JSH 23, NFkappaB transcriptional activity inhibitor (ab144824)
- Datasheet
- References
Overview
-
Product name
JSH 23, NFkappaB transcriptional activity inhibitor -
Description
NFκB transcriptional activity inhibitor -
Biological description
NFκB transcriptional activity inhibitor (IC50 = 7.1 μM). Inhibits LPS-induced nuclear translocation of NFκB. Does not affect IκB degradation. Potentiates the antitumor effects of cisplatin (ab141398). Shows neuroprotective effects in vivo. -
Purity
> 99% -
CAS Number
749886-87-1 -
Chemical structure
Properties
-
Chemical name
4-Methyl-1-N-(3-phenylpropyl)benzene-1,2-diamine -
Molecular weight
240.34 -
Molecular formula
C16H20N2 -
PubChem identifier
16760588 -
Storage instructions
Store at -20°C (desiccating conditions). -
Solubility overview
Soluble in ethanol to 75 mM and in DMSO to 100 mM -
Handling
Toxic, refer to SDS for further information.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES
CC1=CC(=C(C=C1)NCCCC2=CC=CC=C2)N -
Source
Synthetic
-
Research areas
References
This product has been referenced in:
- Kasparkova J et al. Different affinity of nuclear factor-kappa B proteins to DNA modified by antitumor cisplatin and its clinically ineffective trans isomer. FEBS J 281:1393-408 (2014). Read more (PubMed: 24418212) »
- de Vries EM et al. NF?B signaling is essential for the lipopolysaccharide-induced increase of type 2 deiodinase in tanycytes. Endocrinology 155:2000-8 (2014). Read more (PubMed: 24635351) »
- Kumar A et al. JSH-23 targets nuclear factor-kappa B and reverses various deficits in experimental diabetic neuropathy: effect on neuroinflammation and antioxidant defence. Diabetes Obes Metab 13:750-8 (2011). Read more (PubMed: 21447040) »
